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1. Introduction 
Patients with renal failure often have signs and symptoms related to fluid and electrolyte 
disturbances, anemia, malnutrition, bone disease and gastrointestinal problems. One of 
those complications is the uremic encephalopathy. With the introduction of dialysis and 
renal transplantation, the incidence and severity of uremic encephalopathy have declined, 
but many patients fail to fully respond to dialytic therapy. In patients with renal failure, 
encephalopathy is a common problem that may be caused by uremia, thiamine deficiency, 
dialysis, transplant rejection, hypertension, fluid and electrolyte disturbances or drug 
toxicity (Mahoney & Arieff, 1982). In this chapter, the symptoms, pathophysiology and 
treatment of uremic encephalopathy will be discussed. Other neurological complications of 
renal failure are not discussed in this chapter, but were recently reviewed (Brouns & De 
Deyn, 2004). 
2. Clinical presentation 
Uremic encephalopathy may accompany any form of severe acute or chronic renal failure. 
The clinical features appear to be related to the rate of development of renal failure. In 
patients with acute renal failure the symptoms are generally more pronounced and progress 
more rapidly than in patients with chronic renal failure (Aminoff, 1995; Burn & Bates, 1998).  
The symptoms begin insidiously and are often not noticed by the patients but by their 
family members or caregivers. Most encephalopathies are reversible, making prompt 
recognition and treatment important. After hemodialysis, significant improvement of 
uremic encephalopathy occurs, but the level of azotemia correlates poorly with the degree of 
neurological dysfunction (Burn & Bates, 1998). 
2.1 Mental status 
Encephalopathy is a global cerebral dysfunction, often in the absence of primary structural 
brain disease. Nevertheless, in some contexts it can also lead to permanent brain injury, 
while in other cases it is reversible. It can be due to direct injury to the brain, or illness 
remote from the brain. In medical terms it can refer to a wide variety of brain disorders with 
very different etiologies, prognoses and implications.  
Uremic encephalopathy usually presents with alterations in mental status fluctuating from 
mild sensorial clouding to delirium and coma. Impaired attention can be tested by simple 
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bedside tasks such as serial subtraction or naming months of the year in reverse. Other 
common findings include a disturbed sleep-wake cycle, decreased alertness, hypervigilance, 
hallucinations, sensory misperceptions, impaired memory and disorientation. The thought 
process is often disorganized and conversation is confused. Apathy, fatigue, irritability and 
inattentiveness are usually the initial symptoms while confusion, disturbances of sensory 
perception, hallucinations and stupor appear later. The level of alertness reflects the severity 
of the encephalopathy, coma being the most serious stage (Chen, 1996; Earnest, 1993). 
2.2 Associated symptoms 
Besides the alterations in mental status, other associated symptoms are often present. 
Clouding of the sensorium is almost always associated with mild diffuse weakness and a 
variety of motor disturbances. Tremor is common, but other involuntary movements such as 
fasciculations, multifocal myoclonus, chorea, asterixis or seizures are seen in patients at 
various times. Tremor is usually coarse and irregular at a rate of 8-10 Hz. Asterixis or 
flapping tremor is a dramatic problem, with jerking movements arising from lapses of 
posture holding, as of the outstretched hands. It is almost always bilateral. Unilateral 
asterixis suggests an occult structural lesion. Multifocal myoclonus is characterized by 
sudden, non-rhythmic, gross muscle twitching, particularly involving the face and the 
proximal muscles (Chen, 1996). 
Besides the general symptom complex of encephalopathy, headache, focal motor signs and 
the “Uremic twitch convulsive” syndrome can be observed (Aminoff, 1995; De Deyn et al., 
1992b). Focal neurological signs such as hemiparesis, dysarthria, visual abnormalities or 
reflex asymmetry tend to be transient and alternate from side to side (Bolton, 1990). Other 
common associated symptoms include uremic polyneuropathy, pruritus -often leading to 
self induced skin lesions-, and restless-legs syndrome. All these signs fluctuate from day to 
day or sometimes from hour to hour (Aminoff, 1995).  
3. Diagnostic investigations 
A laboratory investigation for encephalopathy includes a complete blood count, electrolyte 
panel and examination of glucose, urea, creatinine, liver enzymes and ammonia. No 
laboratory value, including specific evaluations of the renal function, correlates well with 
clinical symptoms and signs of uremia. Lumbar puncture often reveals elevated protein and 
occasionally a mild pleocytosis. A lumbar puncture is primarily performed to exclude an 
infectious cause of encephalopathy. CT or MRI of the head are only indicated when focal 
signs are present on physical examination and to exclude the presence of a subdural 
hematoma, ischemic stroke or hydrocephalus. Electroencephalographic (EEG) findings in 
uremic encephalopathy are non-specific but correlate with clinical symptoms and, therefore, 
may be of diagnostic value. In addition, it can be useful to exclude other causes of confusion 
such as infection or structural abnormalities. The most common EEG finding is a 
generalized slowing of the normal background. Intermittent frontal rhythmic theta activity 
and paroxysmal, bilateral, high voltage delta waves are also frequent.. Sometimes bilateral 
spike-waves complexes or triphasic waves in the frontal regions are found (Fig. 1). 
Convulsions are often a late stage manifestation of chronic renal failure. Seizures are usually 
generalized tonic-clonic convulsions. Nevertheless, focal motor seizures are not uncommon. 
Epilepsia partialis continua may occur without generalized seizures (Brenner, 1985). 
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In patients with neurologically asymptomatic chronic renal disease, impaired cognitive 
processing can be disclosed by event-related potentials. Increase in P3 latency and decrease 
in P3 amplitude is found (Aminoff, 1995; Burn & Bates, 1998).  
 
Fig. 1. Electroencephalographic findings in a patient with uremic encephalopathy, showing 
generalized slowing with an excess of delta and theta waves and bilateral spikes. 
4. Pathophysiology 
All forms of acute toxic-metabolic encephalopathy interfere with the function of the 
ascending reticular activating system and its projections to cerebral cortex, leading to 
impairment of arousal and awareness (Plum, 1982). The neurophysiologic mechanisms of 
encephalopathy include interruption of polysynaptic pathways and altered excitatory-
inhibitory amino acid balance. Accumulation of metabolites, hormonal disturbance, 
disturbance of the intermediary metabolism and imbalance in excitatory and inhibitory 
neurotransmitters have been identified as contributing factors. 
4.1 Uremic toxins 
Renal failure results in accumulation of numerous organic substances that possibly act as 
uremic neurotoxins, but no single metabolite has been identified as the sole cause of uremia 
(Vanholder et al., 2003b). Symptoms are usually alleviated by dialysis or successful renal 
transplantation. Accumulation of urea, guanidino compounds, uric acid, hippuric acid, 
various amino acids, polypeptides, polyamines, phenols and conjugates of phenol, phenolic 
and indolic acids, acetone, glucuronic acid, carnitine, myoinositol, sulphates and phosphates 
has been reported in the literature (Enomoto et al., 2003; Topczewska-Bruns et al., 2002).  
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By some sources, uremic retention solutes are subdivided into three major classes: 1) small 
solutes (<500 Da) with no known protein binding; 2) solutes with known or likely protein 
binding and 3) middle molecules (≥ 500 Da). This classification is based on the characteristics 
that potentially influence their removal pattern during dialysis. Concentrations of 90 uremic 
solutes and ratios between mean uremic and normal concentration were reported by 
Vanholder et al. (2003a). Their meta-analysis illustrates the complexity of uremic retention. Not 
all solutes are retained to the same extend, and their retention is often not in correlation with 
the current markers, urea and creatinine. This is due to their molecular weight, protein 
binding, and/or multicompartmental behavior (Vanholder et al., 2001; Vanholder & De Smet, 
1999). In addition, a high concentration is not necessarily related to a strong biologic activity. 
For example, the two molecules with the highest concentration (urea and creatinine) are 
known for their relatively limited biologic activity (Vanholder et al., 2001; Vanholder & De 
Smet, 1999). This indicates that removal strategies should be designed in such a way that not 
only the standard molecules, but also other molecules that might be important in the 
deterioration of the clinical condition, can be removed efficiently.  
Urea has been used as a marker of uremic retention and removal for several years (Gotch & 
Sargent, 1985), and its removal is directly correlated with patient survival (Owen, Jr. et al., 
1993). Nevertheless, there are very few studies demonstrating a direct biologic impact of 
urea at currently encountered uremic concentrations (Vanholder & De Smet, 1999), and 
those studies show an impact that not necessarily concentrates on key organic functions in 
the biochemical/biological status of the human body. When urea was added to the dialysate 
during a period of several months at concentrations largely exceeding those currently 
encountered in dialyzed uremics, uremic symptomatology was not consistently altered over 
the entire study period (Johnson et al., 1972), again suggesting that urea by itself is not very 
important in the development of uremic toxicity. It is difficult to explain the apparent 
paradox between the validity of urea as a marker and its presumed lack of toxicity. Of note, 
urea removal seems to be related as a surrogate marker only indirectly to survival, and not 
to quality of life. One possibility to consider is that urea removal by itself does not affect 
survival, but that it is representative for the removal of one or more other solutes with a 
more consistent impact. One such potential culprit is potassium, another small-water 
soluble compound known to substantially affect dialytic survival (Bleyer et al., 1999). 
Another possibility is that, together with urea, other uremic solutes antagonizing its toxic 
impact are retained (Lee et al., 1991). Finally, urea might be at the origin of other, more toxic 
moieties, such as some of the guanidines or carbamylation products (De Deyn et al., 2003; 
De Deyn et al., 2009; Stim et al., 1995; Vanholder & De Smet, 1999) . 
Other metabolic disturbances which may or may not be correlated with the intensity of 
cerebral dysfunction are acidosis, hyponatremia, hyperkalemia, hypocalcemia, 
hypermagnesemia, hyperhydration and dehydration (Bierman, 1970). However, the clinical 
features of uremic encephalopathy do not correlate precisely with any single laboratory 
change. On the other hand, symptoms are usually alleviated by dialysis and are generally 
relieved almost entirely after successful renal transplantation (Brenner et al., 1982; Raskin & 
Fishman, 1976; Teschan & Arieff, 1985).  
4.2 Guanidino compounds 
Among the guanidino compounds, guanidinosuccinic acid, methylguanidine, guanidine 
and creatinine were found to be highly increased in serum, cerebrospinal fluid and brain of 
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uremic patients (De Deyn et al., 2001). It is postulated that these compounds may contribute 
to the epileptic and cognitive symptoms accompanying uremic encephalopathy (D'Hooge et 
al., 1992b; D'Hooge et al., 1992a; Pan et al., 1996). Activation of the excitatory N-methyl-d-
aspartate (NMDA) receptors and concomitant inhibition of inhibitory γ-aminobutyric acid 
(GABA)A-ergic neurotransmission have been proposed as underlying mechanisms (De Deyn 
et al., 2001). This will be further explained in paragraphs 4.2.1 and 4.2.2. 
In addition, transketolase is a thiamine-dependent enzyme of the pentose phosphate 
pathway that is found predominantly in the myelinated structures of the nervous system 
and has been reported to have a critical role in the maintenance of axon-cylinder myelin 
sheats (Dreyfus, 1965; Yonezawa & Iwanami, 1966). This enzyme was shown to be 
significantly inhibited by plasma, cerebrospinal fluid and low molecular weight (<500 
dalton) dialysate fractions obtained from patients with uremia (Sterzel et al., 1971). It is also 
of interest that in uremic subjects, transketolase activity of erythrocytes was found to be 
below normal but increasing following dialytic therapy. Guanidinosuccinic acid was 
capable of reproducing this inhibition which might underlie demyelinative changes 
contributing to both central and peripheral nervous system changes in chronic uremia 
(Lonergan et al., 1971). Moreover, other guanidino compounds, such as guanidine and 
methylguanidine, have been shown in vivo, in experimental animals, to induce clinical 
alterations comparable to those observed in uremia. Methylguanidine induced a syndrome 
similar to the uremic encephalopathy including epilepsy and symptoms similar to the 
uremic “twitch-convulsive” syndrome (Giovannetti et al., 1969; Matsumoto et al., 1976; 
Minot & Dodd, 1933; Mori, 1987). In decreasing potency, guanidinosuccinic acid, 
methylguanidine, guanidine and creatinine inhibited responses to GABA and glycine on 
mouse neurons in cell culture (De Deyn & Macdonald, 1990). The same order of 
epileptogenic potency was found for these uremic guanidine compounds in behavioral 
studies (D'Hooge et al., 1992b). Guanidinosuccinic acid brain concentrations in this chemical 
model of epilepsy were comparable to the levels observed in uremic brain (De Deyn et al., 
1992a). The effects on inhibitory neurotransmission might, in combination with the other 
effects exerted by these toxins, underlie the pathogenesis of the myoclonus and epilepsy. 
Moreover, guanidinosuccinic acid was shown to inhibit excitatory synaptic transmission in 
CA1 region of rat hippocampal slices; this is an effect that might contribute to the cognitive 
symptomatology presenting in uremic encephalopathy (D'Hooge et al., 1991).  
Guanidino compounds are produced as a result of protein and amino acid metabolism. 
Specific guanidino compounds were found to accumulate in biologic fluids and tissues of 
uremic patients. Their levels have been determined in serum, urine and cerebrospinal fluid 
of non-dialyzed and dialyzed renal insufficient patients. Four highly increased compounds 
are creatinine, guanidine, guanidinosuccinic acid and methylguanidine. In addition, 
accumulation of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine was 
reported. In the case of guanidinosuccinic acid, increased cerebrospinal fluid concentrations 
of severely uremic patients were found to be as high as 350 times the mean concentration in 
controls. 
In addition, guanidino compounds are found to stimulate leukocytes, with methylguanidine 
and guanidinoacetic acid significantly enhancing the lipopolysaccharide-stimulated 
production of tumor necrosis factor-α by normal monocytes (Glorieux et al., 2004) and 
SDMA enhancing the monocytic burst via store-operated calcium influx (Schepers et al., 
2009). In addition, guanidino compounds also modify albumin structure in such way that 
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they decrease the protein binding of homocystein (Perna et al., 2004). The resulting free 
active homocysteine consequently contributes to cardiovascular damage.  
Impaired cognition and epileptic symptomatology are the most typical manifestations of 
uremic encephalopathy. However, it is not entirely clear which of the putative uremic toxins 
are responsible for these central nervous system complications in uremia. Probably, the 
complications are due to the combined effects of different neurotoxic compounds. 
Guanidino compounds may play an important role in the etiology of uremic 
encephalopathy and they might contribute to the hyperexcitability of the uremic brain. A 
possible mechanism is described in the next paragraph.  
4.2.1 Effects of uremic guanidino compounds on amino acid receptors 
The four most increased uremic guanidino compounds induced clonic-tonic convulsions in 
adult mice (D'Hooge et al., 1992b). Guanidinosuccinic acid and methylguanidine were 
markedly more potent convulsants than guanidine and creatinine. Brain concentrations 
corresponding with the intraperitoneal CD50 (convulsive dose in 50%) of these convulsants 
were 1328 nmol/g tissue for creatinine, 209 nmol/g tissue for guanidine, 56 nmol/g tissue for 
guanidinosuccinic acid, and 94 nmol/g tissue for methylguanidine. Apparently, brain 
creatinine and guanidinosuccinic acid concentrations, corresponding with intraperitoneal 
doses that induce clonic convulsions in mice, are similar to the concentrations found in brain of 
uremic patients. However, creatinine only induced myoclonic jerking and slight convulsions, 
whereas guanidinosuccinic acid induced vigorous generalized clonic and tonic convulsions. 
The convulsive concentrations in mice of guanidine and methylguanidine were higher than 
those found in uremic brain. Guanidinosuccinic acid is highly increased in uremic serum, 
cerebrospinal fluid, and brain. This compound was shown by our group to be an experimental 
convulsant (D'Hooge et al., 1992b; D'Hooge et al., 1992a). In addition, it appears to be the 
uremic guanidino compound most likely to play an important role in the etiology of the 
hyperexcitability of uremic brain. The compound induced clonic and tonic convulsions as well 
as epileptiform electrocorticographic discharges in adult mice (D'Hooge et al., 1992a). 
Neuroexcitatory effects of these compounds might be due to their actions at inhibitory and 
excitatory amino acid receptors. The four uremic guanidino compounds blocked GABA- 
and glycine-evoked depolarization in mouse spinal cord neurons in primary dissociated cell 
cultures (De Deyn & Macdonald, 1990). Guanidinosuccinic acid was shown to be the most 
potent compound, whereas methylguanidine, guanidine, and creatinine (in decreasing 
order) blocked GABA and glycine responses less potently. It was suggested that the uremic 
guanidino compounds might be blocking the GABAA and glycine receptor-associated 
chloride channel (De Deyn et al., 1991). Later studies using the patch clamp technique 
suggested that guanidinosuccinic acid, methylguanidine, and creatinine may rather act as 
competitive antagonists at the transmitter recognition site of the GABAA receptor (D'Hooge 
et al., 1999). Depending on the clamping potential, GABA-evoked outward or inward 
whole-cell currents, which were blocked by the GABAA receptor antagonist bicuculline. 
Guanidinosuccinic acid, methylguanidine, and creatinine dose-dependently block these 
GABA-evoked whole-cell currents (D'Hooge et al., 1999). Guanidinosuccinic acid was 
shown to be more potent than methylguanidine or creatinine, but all three blocked inward 
as well as outward GABA-evoked current. The GABAA and glycine receptor antagonism 
that was shown in in vitro experiments, might underlie the convulsive action of the uremic 
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guanidino compounds in vivo and might contribute to the epileptic symptomatology in 
uremia. However, in the case of guanidinosuccinic acid induced clonic convulsions, 
antiepileptic drugs like diazepam or phenobarbital did not or only slightly attenuate these 
convulsions (D'Hooge et al., 1992a; D'Hooge et al., 1993). Competitive and noncompetitive 
NMDA receptor antagonists, on the other hand, did effectively block these convulsions 
(D'Hooge et al., 1993). Also, guanidinosuccinic acid potentiated NMDA- but not glutamate- 
or kainate- induced convulsions. These findings suggested that, in addition to the blockade 
of GABAergic inhibition, NMDA receptors were somehow involved in the 
guanidinosuccinic acid induced convulsions. The hypothetical activation of NMDA receptor 
by guanidinosuccinic acid was first corroborated by Reynolds and Rothermund (Reynolds 
& Rothermund, 1992). They found that creatinine, guanidine and methylguanidine blocked 
the NMDA receptor-associated ionophore in a similar manner to magnesium, but that 
guanidinosuccinic acid was able to enhance [3H]dizocilpine binding to rat brain membranes, 
and increase intracellular [Ca2+] in rat forebrain neurons. Both latter effects are indicative of 
agonist actions of guanidinosuccinic acid at the NMDA receptor. We found behavioral and 
electrophysiological evidence that guanidinosuccinic acid (but not methylguanidine) acts as 
a selective agonist at NMDA-type excitatory amino acid receptors in a similar manner to the 
structurally related L-aspartate (D'Hooge et al., 1996). Guanidinosuccinic acid was shown to 
abolish the excitatory postsynaptic potential recorded from CA1 region in rat hippocampal 
slices (D'Hooge et al., 1991; D'Hooge et al., 1996). The inhibition of this effect by a selective 
NMDA receptor antagonist indicated that this was probably due to NMDA receptor-
mediated depolarization of hippocampal neurons (D'Hooge et al., 1996). Pan et al. (Pan et 
al., 1996) demonstrated that intrahippocampal injection of guanidinosuccinic acid in rats 
induces epileptiform electrographic discharges, and leads to hippocampal damage, which 
could be blocked by treatment with the NMDA receptor antagonist ketamine. It is indeed 
well established that the application of NMDA agonists, even in amounts that are not 
immediately toxic, induce neurodegeneration. Excessive calcium influx through NMDA 
receptor-associated ion channels leads to loss of mitochondrial and nuclear function, 
activation of proteases and other calcium-dependent enzymes, and ultimate excitotoxic cell 
death. The effect of intrahippocampal guanidinosuccinic acid injection on both (cognitive) 
behavior and hippocampal volume in mice was investigated as well (Torremans et al., 2005). 
A significant dose-dependent effect of intrahippocampal injection of guanidinosuccinic acid 
on cognitive performance, activity, and social exploratory behavior was observed. Volume 
of hippocampal cornu ammonis region decreased significantly and dose-dependently after 
guanidinosuccinic acid injection. Systemic guanidinosuccinic acid injection increased cGMP 
concentration in hippocampal formation. Knowledge of neurotoxic effects and mechanisms 
of action of guanidinosuccinic acid and other uremic retention solutes could help in the 
development of more efficient treatment of uremic patients.  
4.2.2 Hypothetical mechanism of neuroexcitation by uremic guanidino compounds 
Based on the results summarized above, a hypothetical mechanism for the action of uremic 
guanidino compounds on glutamatergic transmission in the central nervous system was 
proposed by De Deyn et al. (De Deyn et al., 2009) (Fig. 2). A simplified model of the Schaffer 
collateral-pyramidal cell synapse in the CA1 region of the rodent hippocampus was used 
(Collingridge & Lester, 1989). In a changed form, the proposed mechanism might also apply 
to other glutamatergic pathways. The mechanism could explain the neuroexcitatory and 
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convulsant actions of guanidinosuccinic acid (and other uremic guanidino compounds) in 
experimental animals, but it might also link uremic guanidino compounds to uremia-
associated epileptic symptomatology. In CA1 region, fast synaptic events are carried by two 
kinds of ionotropic excitatory amino acid receptors: a-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA) and NMDA receptors (Collingridge & Lester, 1989). Both 
receptor types react to endogenously released L-glutamate. During low-frequency 
transmission, the NMDA receptor- associated ionic channel is voltage dependently blocked 
by Mg2+. Low-frequency activation of AMPA receptors does elicit Na+ influx, but this 
depolarizing current does not provide sufficient membrane depolarization to reduce the 
Mg2+ block on the NMDA receptor. GABAergic interneurons mediate powerful feedforward 
as well as feedback synaptic inhibition. Endogenously released GABA binds to GABAA 
receptors, activating the ligand-gated ionic channel of the receptor, and eliciting 
hyperpolarizing chloride influx. 
 
Fig. 2. Excitatory effects of uremic guanidino compounds. Hypothetical mechanism of action 
of guanidinosuccinic acid on synaptic transmission in rat hippocampal CA1 region. During 
low-frequency transmission, the excitatory neurotransmitter L-glutamate is released by the 
afferent terminal and binds to AMPA and NMDA receptors (NMDA-R). GABAergic 
interneurons provide synaptic inhibition through activation of GABAA receptors (GABA-R) 
and chloride influx. Due to insufficient membrane depolarization, the voltage dependent 
Mg2+ block on the NMDA-R is not lifted. However, in the presence of increased 
guanidinosuccinic acid levels, blocked GABAA receptors, and depolarizing effects of other 
uremic guanidino compounds, the Mg2+ block may be lifted from the NMDA-R. Activation 
of NMDA-Rs elicits Ca2+ influx through NMDA-R ionophores and activation of Ca2+-
triggered events such as activation of nitric oxide synthase (NOS) leading to nitric oxide 
(NO) production and increased glutamate release presynaptically (De Deyn et al., 2009). 
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According to the proposed mechanism (Fig. 2), guanidinosuccinic acid evokes activation of 
NMDA receptors in conjunction with blockade of GABAA receptor ionophores. Under these 
conditions, the pyramidal cells might be sufficiently depolarized to reduce the Mg2+ block 
on NMDA receptors. Activation of NMDA receptors elicits Ca2+ influx, potentially causing 
calcium-mediated neurotoxicity. Production of nitric oxide through calcium dependent 
activation of nitric oxide synthase could be one of the mechanisms involved in the sustained 
excitatory activity following guanidinosuccinic acid application. As already mentioned, Pan 
et al. (Pan et al., 1996) have shown NMDA receptor-mediated hippocampal damage 
following intrahippocampal injection of guanidinosuccinic acid in rats. In uremic brain, the 
depolarizing effects of guanidino compounds and other uremic toxins might enhance the 
effect of guanidinosuccinic acid. The joint presence of increased levels of uremic guanidino 
compounds could increase the block on GABAA receptors since it has been shown that, e.g., 
co-application of guanidine and methylguanidine results in a significantly larger inhibition 
of GABA responses than when either of these guanidino compounds were applied alone (De 
Deyn & Macdonald, 1990). Moreover, guanidino compounds were shown to have other 
neurotoxic effects, which might also lead to neuronal depolarization (Mori, 1987). One such 
effect is the inhibition of brain Na+⁄K+-ATPase by methylguanidine (Yokoi et al., 1984).  
4.3 Energy metabolism 
Besides toxins, evidence indicates that energy metabolism might play a role. Experimental 
animal studies and in vitro tests demonstrated disturbances of intermediary metabolism. In 
the brain of rats with acute renal failure, creatine phosphate, adenosine triphosphate and 
glucose levels are increased in the presence of decreased adenosine monophosphate, 
adenosine diphosphate and lactate levels. Thus, the uremic brain in experimental uremia 
appears to use less adenosine triphosphate and to produce less aadenosine diphosphate, 
adenosine monoposphate and lactate. These changes are associated with a decrease in both 
brain metabolic rate and cerebral oxygen consumption (Mahoney et al., 1984; Van den Noort 
et al., 1968) and are consistent with a generalized decrease in brain energy use. Moreover, an 
inhibition of cerebral sodium-potassium-ATPase was shown in experimental uremic 
animals (Burn & Bates, 1998; Minkoff et al., 1972). This could correlate with the elevation in 
intracellular sodium and could therefore be associated with some of the aspects of cerebral 
dysfunction, particularly with seizure activity. More recent studies on metabolically active 
and purified brain synaptosomes showed that both the sodium potassium adenosine 
triphosphate pump and several calcium pumps are altered in uremic rats (Fraser et al., 
1985a; Fraser et al., 1985b). 
4.4 Hormonal disturbances  
The role of hormonal disturbances in the genesis of the uremic syndrome should be 
considered as well. Blood levels of many hormones such as parathyroid hormone, insulin, 
growth hormone, glucagon, thyrotropin, prolactin, luteinizing hormone and gastrin are 
elevated in patients with uremia. One of the major hormonal imbalances in uremia is the 
rise in the levels of parathyroid hormone. The possible pathophysiological role of 
parathyroid hormone in the development of nervous system complications in uremia has 
been considerably discussed (Heath et al., 1980; Slatopolsky et al., 1980). Parathyroid 
hormone appears to produce some of the central nervous system changes of uremia in 
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healthy dogs (Guisado et al., 1975). Previously parathyroidectomised rats, subjected to 
bilateral uretral ligation, were protected against the uremia-induced alterations of 
somatosensory evoked potentials (Kanda et al., 1990). In humans, parathyroid hormone 
produced central nervous system effects, even in the absence of renal failure (Cogan et al., 
1978). The mechanisms by which parathyroid hormone might impair central nervous 
system function are not completely understood. However, the increased calcium content in 
diverse tissues, among which brain, in patients with uremia and secondary 
hyperparathyroidism suggests that parathyroid hormone may somehow facilitate the entry 
of calcium in these tissues (Akmal et al., 1984; Burn & Bates, 1998; Massry, 1985). Since 
calcium is an essential mediator of neurotransmitter release and plays an important role in 
intracellular metabolic and enzymatic processes, alterations of brain calcium, may possibly 
disrupt cerebral function by interfering with any of these processes (Rasmussen, 1986). 
Brain edema and alterations in water transport have also been implicated (Arieff et al., 1973; 
Arieff & Massry, 1974). Decreased brain energy demand, free amino acid changes, and 
blood-brain barrier derangement have been shown to be involved in both acute and chronic 
uremic encephalopathy (Jeppsson et al., 1982; Kikuchi et al., 1983; Mahoney et al., 1984). In a 
mouse model for acute kidney injury, it was demonstrated that pyknotic neuronal cells were 
significantly increased in region CA1 of the hippocampus. In addition, acute kidney injury 
resulted in significant increases in levels of the chemokines keratinocyte-derived 
chemoattractant and G-CSF in the brain at 24h after ischemia. On the other hand, brain 
water content during acute kidney injury was not increased or even decreased, while an 
increase in microvascular permeability in the brain was observed (Liu et al., 2008).  
5. Treatment 
5.1 Dialytic treatment 
Acute uremic encephalopathy reverses with hemodialysis or peritoneal dialysis, although a 
lag time of 1 to 2 days is usually required before mental status clears. Subtle cognitive 
difficulties may persist even after dialysis. A disadvantage of dialysis is its non-specificity 
and the fact that it removes also essential compounds. In addition, lipophilic compounds, 
which may be responsible at least in part for functional alterations in uremia, are 
inadequately removed by dialysis. Also, renal transplant can be considered a treatment. 
However, uremic encephalopathy can complicate renal transplant. 
5.2 Non-dialytic treatment 
Removal of uremic toxins are also influenced by intestinal intake and preservation of the 
renal function. Intestinal uptake can be reduced by influencing dietary uptake or by oral 
administration of absorbents. Approaches that have been shown to result in decrease in 
concentration include a low protein diet, administration of prebiotics such as resistant starch 
(Birkett, 1996) or probiotics such as bifidobacterium (Taki, 2005). Preservation of residual 
renal function may also be an important manner to pursue additional removal of retention 
solutes. 
Acute renal failure induces brain mitochondrial dysfunction. Administration of the 
antioxidants N-acetylcysteine and deferoxamine was able to prevent the inhibition of 
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mitochondrial respiratory chain complexes I and IV (Barbosa et al., 2010). Therefore, it can 
be speculated that excessive reactive species generation might contribute to the 
neuropathology associated with acute renal failure. Creatine kinase was inhibited in 
prefrontal cortex, cerebral cortex and hippocampus in an animal model of acute renal 
failure. In this way, diminished creatine kinase might be involved in the cognitive 
impairment in patients with uremic encephalopathy. The inhibition of creatine kinase was 
prevented by antioxidants. It was speculated that oxidative stress might be involved in the 
mechanism of creatine kinase activity inhibition (Di-Pietro et al., 2008). In addition, 
increased malondialdehyde and diminished glutathione levels in brain of rats submitted to 
a model of chronic renal failure (Sener et al., 2007). 
6. Dialysis disequilibrium  
Dialysis disequilibrium syndrome occurs in patients receiving hemodialysis. The symptoms 
include headache, nausea, emesis, blurred vision, muscular twitching, disorientation, 
delirium, hypertension, tremors and seizures. The condition tends to be self-limited and 
subsides over several hours. It is attributed to a reverse urea effect. Urea is cleared more 
slowly from the brain than from the blood, an effect that causes an osmotic gradient leading 
to the net flow into the brain and to transient cerebral edema (Bucurescu, 2008). 
7. Dialysis encephalopathy  
Some patients undergoing long-term dialysis develop dialysis encephalopathy or dialysis 
dementia. This is a subacute, progressive and often fatal disease. It is believed to be a part of 
a multiple system disease that includes encephalopathy, osteomalacic bone disease, 
proximal myopathy and anemia. Other symptoms include dysarthria, aparaxia, personality 
changes, psychosis, myoclonus, seizures and finally dementia. In most cases, the condition 
progress to death in six months (Brouns, 2004). 
8. Conclusion 
In spite of the introduction of different dialytic procedures during the last decades, the 
neurological complications of uremia, although declined, remain manifold and sometimes 
serious. Although onset of uremic encephalopathy is often insidious, early recognition is 
very important as it comes to treatment. The different symptoms to be looked for are 
reviewed in this chapter. Urea is often used as a marker of dialytic efficiency, but has limited 
biological activity. Therefore, in the future, removal strategies should be designed in such a 
way that not only the standard molecules, but also other molecules that might be important 
in the deterioration of the clinical condition, can be removed efficiently. In contrast, the 
guanidino compounds are of great biological relevance. Those molecules have been shown 
to have neuroexcitatory effects and lead to convulsions. Activation of the excitatory N-
methyl-d-aspartate (NMDA) receptors and concomitant inhibition of inhibitory γ-
aminobutyric acid (GABA)A-ergic neurotransmission have been proposed as underlying 
mechanisms. In this chapter, putative action mechanisms are enlightened but those 
pathways remain to be corroborated. Knowledge of neurotoxic effects and mechanisms of 
action of guanidinosuccinic acid and other uremic retention solutes could add to the limited 
treatment options of uremic patients. 
www.intechopen.com
 
Miscellanea on Encephalopathies – A Second Look 
 
34
9. References 
Akmal, M., Goldstein, D.A., Multani, S., Massry, S.G. (1984). Role of uremia, brain calcium, 
and parathyroid hormone on changes in electroencephalogram in chronic renal 
failure. Am. J. Physiol Vol. 246, No.5 Pt 2 F575-F579 
Aminoff, M.J. (1995). Neurological dysfunction and kidney disease, In: Neurology and general 
medicine, N.H.Raskin (Ed.), pp. 303-319, Churchill Livingstone, Philadelphia. 
Arieff, A.I., Massry, S.G. (1974). Calcium metabolism of brain in acute renal failure. Effects 
of uremia, hemodialysis, and parathyroid hormone. J. Clin. Invest Vol. 53, No.2 387-
392 
Arieff, A.I., Massry, S.G., Barrientos, A., Kleeman, C.R. (1973). Brain water and electrolyte 
metabolism in uremia: effects of slow and rapid hemodialysis. Kidney Int. Vol. 4, 
No.3 177-187 
Barbosa, P.R., Cardoso, M.R., Daufenbach, J.F., Goncalves, C.L., Machado, R.A., Roza, C.A., 
Scaini, G., Rezin, G.T., Schuck, P.F., Dal-Pizzol, F., Streck, E.L. (2010). Inhibition of 
mitochondrial respiratory chain in the brain of rats after renal ischemia is 
prevented by N-acetylcysteine and deferoxamine. Metab Brain Dis. Vol. 25, No.2 
219-225 
Bierman, E.L. (1970). Abnormalities of carbohydrate and lipid metabolism in uremia. Arch. 
Intern. Med. Vol. 126, No.5 790-792 
Birket A., Muir J., Phillips J., Jones G. O'Dea K. (1996) Resistant starch lowers fecal 
concentrations of ammonia en phenols in humans. Am. J. Clin. Nutr. 63; 766 
Bleyer, A.J., Russell, G.B., Satko, S.G. (1999). Sudden and cardiac death rates in hemodialysis 
patients. Kidney Int. Vol. 55, No.4 1553-1559 
Bolton C.F., Young G.B. (1990) Uremic encephalopathy. In: Neurological complications of renal 
disease Bolton C.F., Young G.B. 44 Buttersworth 
Brenner R.P. (1985) The electroencephalogram in altered states of consciousness. Neurol Clin, 
3, 615  
Brenner, B.M., Meyer, T.W., Hostetter, T.H. (1982). Dietary protein intake and the 
progressive nature of kidney disease: the role of hemodynamically mediated 
glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, 
renal ablation, and intrinsic renal disease. N. Engl. J. Med. Vol. 307, No.11 652-659 
Brouns R, De Deyn PP. (2004). Neurological complications in renal failure: a review. Clin. 
Neurol. Neurosurg. Vol. 107, No.1 1-16 
Bucurescu G. (2008) Uremic encephalopathy. E-medicine  
Burn, D.J., Bates, D. (1998). Neurology and the kidney. J. Neurol. Neurosurg. Psychiatry Vol. 
65, No.6 810-821 
Cogan, M.G., Covey, C.M., Arieff, A.I., Wisniewski, A., Clark, O.H., Lazarowitz, V., Leach, 
W. (1978). Central nervous system manifestations of hyperparathyroidism. Am. J. 
Med. Vol. 65, No.6 963-970 
Collingridge, G.L., Lester, R.A. (1989). Excitatory amino acid receptors in the vertebrate 
central nervous system. Pharmacol. Rev. Vol. 41, No.2 143-210 
Chen R. (1996) Metaolic encephalopathies. In: Baillere's clinical neurology Bolton C.F., Young 
G.B. p. 577 Balliere Tindall 
D'Hooge, R., De Deyn, P.P., Van de Vijver, G., Antoons, G., Raes, A., Van Bogaert, P.P. (1999). 
Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell 
currents in mouse spinal cord neurones. Neurosci. Lett. Vol. 265, No.2 83-86 
www.intechopen.com
 
Uremic Encephalopathy 
 
35 
D'Hooge, R., Manil, J., Colin, F., De Deyn, P.P. (1991). Guanidinosuccinic acid inhibits 
excitatory synaptic transmission in CA1 region of rat hippocampal slices. Ann. 
Neurol. Vol. 30, No.4 622-623 
D'Hooge, R., Pei, Y.Q., De Deyn, P.P. (1993). N-methyl-D-aspartate receptors contribute to 
guanidinosuccinate-induced convulsions in mice. Neurosci. Lett. Vol. 157, No.2 123-
126 
D'Hooge, R., Pei, Y.Q., Manil, J., De Deyn, P.P. (1992a). The uremic guanidino compound 
guanidinosuccinic acid induces behavioral convulsions and concomitant 
epileptiform electrocorticographic discharges in mice. Brain Res. Vol. 598, No.1-2 
316-320 
D'Hooge, R., Pei, Y.Q., Marescau, B., De Deyn, P.P. (1992b). Convulsive action and toxicity 
of uremic guanidino compounds: behavioral assessment and relation to brain 
concentration in adult mice. J. Neurol. Sci. Vol. 112, No.1-2 96-105 
D'Hooge, R., Raes, A., Lebrun, P., Diltoer, M., Van Bogaert, P.P., Manil, J., Colin, F., De 
Deyn, P.P. (1996). N-methyl-D-aspartate receptor activation by guanidinosuccinate 
but not by methylguanidine: behavioural and electrophysiological evidence. 
Neuropharmacology Vol. 35, No.4 433-440 
De Deyn, P.P., D'Hooge, R., Marescau, B., Pei, Y.Q. (1992a). Chemical models of epilepsy 
with some reference to their applicability in the development of anticonvulsants. 
Epilepsy Res. Vol. 12, No.2 87-110 
De Deyn, P.P., D'Hooge, R., Van Bogaert, P.P., Marescau, B. (2001). Endogenous guanidino 
compounds as uremic neurotoxins. Kidney Int. Suppl Vol. 78, S77-S83 
De Deyn, P.P., Macdonald, R.L. (1990). Guanidino compounds that are increased in 
cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine 
responses on mouse neurons in cell culture. Ann. Neurol. Vol. 28, No.5 627-633 
De Deyn, P.P., Marescau, B., Macdonald, R.L. (1991). Guanidino compounds that are 
increased in hyperargininemia inhibit GABA and glycine responses on mouse 
neurons in cell culture. Epilepsy Res. Vol. 8, No.2 134-141 
De Deyn, P.P., Saxena, V.K., Abts, H., Borggreve, F., D'Hooge, R., Marescau, B., Crols, R. 
(1992b). Clinical and pathophysiological aspects of neurological complications in 
renal failure. Acta Neurol. Belg. Vol. 92, No.4 191-206 
De Deyn, P.P., Vanholder, R., Eloot, S., Glorieux, G. (2009). Guanidino compounds as uremic 
(neuro)toxins. Semin. Dial. Vol. 22, No.4 340-345 
De Deyn PP, Vanholder R, D'Hooge R. (2003). Nitric oxide in uremia: effects of several 
potentially toxic guanidino compounds. Kidney Int Suppl. Vol. 84 S25-8. 
Di-Pietro, P.B., Dias, M.L., Scaini, G., Burigo, M., Constantino, L., Machado, R.A., Dal-Pizzol, 
F., Streck, E.L. (2008). Inhibition of brain creatine kinase activity after renal 
ischemia is attenuated by N-acetylcysteine and deferoxamine administration. 
Neurosci. Lett. Vol. 434, No.1 139-143 
Dreyfus, P. (1965). The regional distribution of transketolase in the normal and the thiamine 
deficient nervous system. J. Neuropathol. Exp. Neurol. Vol. 24, 119-129 
Earnest M.P. (1993) Metabolic encephalopathies and coma from medical causes. In: 
Management of the acutely ill neurological patient. Churchill livingstone 1 
Enomoto, A., Takeda, M., Taki, K., Takayama, F., Noshiro, R., Niwa, T., Endou, H. (2003). 
Interactions of human organic anion as well as cation transporters with indoxyl 
sulfate. Eur. J. Pharmacol. Vol. 466, No.1-2 13-20 
www.intechopen.com
 
Miscellanea on Encephalopathies – A Second Look 
 
36
Fraser, C.L., Sarnacki, P., Arieff, A.I. (1985a). Abnormal sodium transport in synaptosomes 
from brain of uremic rats. J. Clin. Invest Vol. 75, No.6 2014-2023 
Fraser, C.L., Sarnacki, P., Arieff, A.I. (1985b). Calcium transport abnormality in uremic rat 
brain synaptosomes. J. Clin. Invest Vol. 76, No.5 1789-1795 
Giovannetti, S., Biagini, M., Balestri, P.L., Navalesi, R., Giagnoni, P., De, M.A., Ferro-Milone, 
P., Perfetti, C. (1969). Uraemia-like syndrome in dogs chronically intoxicated with 
methylguanidine and creatinine. Clin. Sci. Vol. 36, No.3 445-452 
Glorieux, G.L., Dhondt, A.W., Jacobs, P., Van Langeraert, J., Lameire, N.H., De Deyn, P.P., 
Vanholder, R.C. (2004). In vitro study of the potential role of guanidines in 
leukocyte functions related to atherogenesis and infection. Kidney Int. Vol. 65, No.6 
2184-2192 
Gotch, F.A., Sargent, J.A. (1985). A mechanistic analysis of the National Cooperative Dialysis 
Study (NCDS). Kidney Int. Vol. 28, No.3 526-534 
Guisado, R., Arieff, A.I., Massry, S.G., Lazarowitz, V., Kerian, A. (1975). Changes in the 
electroencephalogram in acute uremia. Effects of parathyroid hormone and brain 
electrolytes. J. Clin. Invest Vol. 55, No.4 738-745 
Heath, H., Hodgson, S.F., Kennedy, M.A. (1980). Primary hyperparathyroidism. Incidence, 
morbidity, and potential economic impact in a community. N. Engl. J. Med. Vol. 
302, No.4 189-193 
Jeppsson, B., Freund, H.R., Gimmon, Z., James, J.H., von Meyenfeldt, M.F., Fischer, J.E. 
(1982). Blood-brain barrier derangement in uremic encephalopathy. Surgery Vol. 92, 
No.1 30-35 
Johnson, W.J., Hagge, W.W., Wagoner, R.D., Dinapoli, R.P., Rosevear, J.W. (1972). Effects of 
urea loading in patients with far-advanced renal failure. Mayo Clin. Proc. Vol. 47, 
No.1 21-29 
Kanda, F., Jinnai, K., Tada, K., Fujita, T. (1990). Somatosensory evoked potentials in acute 
renal failure: effect of parathyroidectomy. Kidney Int. Vol. 38, No.6 1085-1088 
Kikuchi, S., Matsumoto, H., Ito, M. (1983). Free amino acid changes in the cerebral cortex of 
experimental uremic rat. Neurochem. Res. Vol. 8, No.3 313-318 
Lee, J.A., Lee, H.A., Sadler, P.J. (1991). Uraemia: is urea more important than we think? 
Lancet Vol. 338, No.8780 1438-1440 
Liu, M., Liang, Y., Chigurupati, S., Lathia, J.D., Pletnikov, M., Sun, Z., Crow, M., Ross, C.A., 
Mattson, M.P., Rabb, H. (2008). Acute kidney injury leads to inflammation and 
functional changes in the brain. J. Am. Soc. Nephrol. Vol. 19, No.7 1360-1370 
Lonergan, E.T., Semar, M., Sterzel, R.B., Treser, G., Needle, M.A., Voyles, L., Lange, K. 
(1971). Erythrocyte transketolase activity in dialyzed patients. A reversible 
metabolic lesion of uremia. N. Engl. J. Med. Vol. 284, No.25 1399-1403 
Mahoney, C.A., Arieff, A.I. (1982). Uremic encephalopathies: clinical, biochemical, and 
experimental features. Am. J. Kidney Dis. Vol. 2, No.3 324-336 
Mahoney, C.A., Sarnacki, P., Arieff, A.I. (1984). Uremic encephalopathy: role of brain energy 
metabolism. Am. J. Physiol Vol. 247, No.3 Pt 2 F527-F532 
Massry, S.G. (1985). Current status of the role of parathyroid hormone in uremic toxicity. 
Contrib. Nephrol. Vol. 49, 1-11 
Matsumoto, M., Kobayashi, K., Kishikawa, H., Mori, A. (1976). Convulsive activity of 
methylguanidine in cat and rabbits. IRCS Med. Sci. Vol. 4, 65 
www.intechopen.com
 
Uremic Encephalopathy 
 
37 
Minkoff, L., Gaertner, G., Darab, M., Mercier, C., Levin, M.L. (1972). Inhibition of brain 
sodium-potassium ATPase in uremic rats. J. Lab Clin. Med. Vol. 80, No.1 71-78 
Minot, A.S., Dodd, K. (1933). Guanidine intoxication: a complicating factor in certain clinical 
conditions in children. Am. J. Dis. Child Vol. 43, No.3 522-542 
Mori, A. (1987). Biochemistry and neurotoxicology of guanidino compounds. History and 
recent advances. Pavlov. J. Biol. Sci. Vol. 22, No.3 85-94 
Owen, W.F., Jr., Lew, N.L., Liu, Y., Lowrie, E.G., Lazarus, J.M. (1993). The urea reduction 
ratio and serum albumin concentration as predictors of mortality in patients 
undergoing hemodialysis. N. Engl. J. Med. Vol. 329, No.14 1001-1006 
Pan, J.C., Pei, Y.Q., An, L., Lai, L., D'Hooge, R., De Deyn, P.P. (1996). Epileptiform activity 
and hippocampal damage produced by intrahippocampal injection of 
guanidinosuccinic acid in rat. Neurosci. Lett. Vol. 209, No.2 121-124 
Perna, A.F., Ingrosso, D., Satta, E., Lombardi, C., Galletti, P., D'Aniello, A., De Santo, N.G. 
(2004). Plasma protein aspartyl damage is increased in hemodialysis patients: 
studies on causes and consequences. J. Am. Soc. Nephrol. Vol. 15, No.10 2747-2754 
Plum F., Posner J.B. (1982) The diagnosis of stupor and coma. FA Davis company p.177 
Raskin, N.H., Fishman, R.A. (1976). Neurologic disorders in renal failure (first of two parts). 
N. Engl. J. Med. Vol. 294, No.3 143-148 
Rasmussen, H. (1986). The calcium messenger system (1). N. Engl. J. Med. Vol. 314, No.17 
1094-1101 
Reynolds, I.J. and Rothermund, K. (1992). Multiple modes of NMDA receptor regulation by 
guanidines, In: Guanidino compounds in biology and medicine, P.P.De Deyn, 
B.Marescau, V.Stalon, I.A.Qureshi (Eds.), pp. 441-448, John Libbey, London. 
Schepers, E., Glorieux, G., Dhondt, A., Leybaert, L., Vanholder, R. (2009). Role of symmetric 
dimethylarginine in vascular damage by increasing ROS via store-operated calcium 
influx in monocytes. Nephrol. Dial. Transplant. Vol. 24, No.5 1429-1435 
Sener, G., Sakarcan, A., Sehirli, O., Eksioglu-Demiralp, E., Sener, E., Ercan, F., Gedik, N., 
Yegen, B.C. (2007). Chronic renal failure-induced multiple-organ injury in rats is 
alleviated by the selective CysLT1 receptor antagonist montelukast. Prostaglandins 
Other Lipid Mediat. Vol. 83, No.4 257-267 
Slatopolsky, E., Martin, K., Hruska, K. (1980). Parathyroid hormone metabolism and its 
potential as a uremic toxin. Am. J. Physiol Vol. 239, No.1 F1-12 
Sterzel, R.B., Semar, M., Lonergan, E.T., Treser, G., Lange, K. (1971). Relationship of nervous 
tissue transketolase to the neuropathy in chronic uremia. J. Clin. Invest Vol. 50, 
No.11 2295-2304 
Stim, J., Shaykh, M., Anwar, F., Ansari, A., Arruda, J.A., Dunea, G. (1995). Factors 
determining hemoglobin carbamylation in renal failure. Kidney Int. Vol. 48, No.5 
1605-1610 
Taki K., Takayama F., Niwa T. (2005) Beneficial effects of bifidobacteria in a gastroresistant 
searnless capsule on hyperhomocysteinemie in hemodialysis patients. J. ren. nutr. 
15; 77 
Teschan, P.E. and Arieff, A.I. (1985). Uremic and dialysis encephalopathies, In: Cerebral 
energy metabolism and metabolic encephalopathy, D.W.McCandless (Ed.), pp. 263-286, 
Plenum Press, New York. 
www.intechopen.com
 
Miscellanea on Encephalopathies – A Second Look 
 
38
Topczewska-Bruns, J., Pawlak, D., Chabielska, E., Tankiewicz, A., Buczko, W. (2002). 
Increased levels of 3-hydroxykynurenine in different brain regions of rats with 
chronic renal insufficiency. Brain Res. Bull. Vol. 58, No.4 423-428 
Torremans, A., Marescau, B., Van, D.D., Van, G.C., Van, M.F., Van Bogaert, P.P., D'Hooge, 
R., de, V.J., De Deyn, P.P. (2005). GSA: behavioral, histological, electrophysiological 
and neurochemical effects. Physiol Behav. Vol. 84, No.2 251-264 
Van den Noort, S., Eckel, R.E., Brine, K., Hrdlicka, J.T. (1968). Brain metabolism in uremic 
and adenosine-infused rats. J. Clin. Invest Vol. 47, No.9 2133-2142 
Vanholder, R., Argiles, A., Baurmeister, U., Brunet, P., Clark, W., Cohen, G., De Deyn, P.P., 
Deppisch, R., scamps-Latscha, B., Henle, T., Jorres, A., Massy, Z.A., Rodriguez, M., 
Stegmayr, B., Stenvinkel, P., Wratten, M.L. (2001). Uremic toxicity: present state of 
the art. Int. J. Artif. Organs Vol. 24, No.10 695-725 
Vanholder, R., De Smet, R. (1999). Pathophysiologic effects of uremic retention solutes. J. 
Am. Soc. Nephrol. Vol. 10, No.8 1815-1823 
Vanholder, R., De Smet, R., Glorieux, G., Argiles, A., Baurmeister, U., Brunet, P., Clark, W., 
Cohen, G., De Deyn, P.P., Deppisch, R., Descamps-Latscha, B., Henle, T., Jorres, A., 
Lemke, H.D., Massy, Z.A., Passlick-Deetjen, J., Rodriguez, M., Stegmayr, B., 
Stenvinkel, P., Tetta, C., Wanner, C., Zidek, W. (2003a). Review on uremic toxins: 
classification, concentration, and interindividual variability. Kidney Int. Vol. 63, 
No.5 1934-1943 
Vanholder, R., De, S.R., Glorieux, G., Argiles, A., Baurmeister, U., Brunet, P., Clark, W., 
Cohen, G., De Deyn, P.P., Deppisch, R., scamps-Latscha, B., Henle, T., Jorres, A., 
Lemke, H.D., Massy, Z.A., Passlick-Deetjen, J., Rodriguez, M., Stegmayr, B., 
Stenvinkel, P., Tetta, C., Wanner, C., Zidek, W. (2003b). Review on uremic toxins: 
classification, concentration, and interindividual variability. Kidney Int. Vol. 63, 
No.5 1934-1943 
Yokoi, I., Toma, J., Mori, A. (1984). The effect of homoarginine on the EEG of rats. 
Neurochem. Pathol. Vol. 2, No.4 295-300 
Yonezawa, T., Iwanami, H. (1966). An experimental study of thiamine deficiency in nervous 
tissue, using tissue culture technics. J. Neuropathol. Exp. Neurol. Vol. 25, No.3 362-
372 
www.intechopen.com
Miscellanea on Encephalopathies - A Second Look
Edited by Dr. Radu Tanasescu
ISBN 978-953-51-0558-9
Hard cover, 390 pages
Publisher InTech
Published online 25, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book project “Miscellanea on Encephalopathies-a second look” aims to cover some of the important
aspects regarding metabolic, hypoxic, neoplasm- and drug-related encephalopathies, by transmitting valuable
information filtered through the real life clinical and research experience of the authors.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Annemie Van Dijck, Wendy Van Daele and Peter Paul De Deyn (2012). Uremic Encephalopathy, Miscellanea
on Encephalopathies - A Second Look, Dr. Radu Tanasescu (Ed.), ISBN: 978-953-51-0558-9, InTech,
Available from: http://www.intechopen.com/books/miscellanea-on-encephalopathies-a-second-look/uremic-
encephalopathy
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
